Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 285-089-6 | CAS number: 85029-63-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Key value for chemical safety assessment
Effects on fertility
Description of key information
A NOAEL of 1000 mg/kg bw/day for reproductive and developmental effects could be derived from a reliable combined repeated dose and reproduction screening study in rats.
Link to relevant study records
- Endpoint:
- screening for reproductive / developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 28 September 2016 to 07 July 2017
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Reason / purpose for cross-reference:
- reference to same study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 422 (Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening Test)
- Version / remarks:
- Combined Repeated Dose Toxicity Study with the Reproduction/Developmental Toxicity Screening Test” adopted on 29 July 2016
- Deviations:
- no
- Principles of method if other than guideline:
- Not applicable
- GLP compliance:
- yes (incl. QA statement)
- Limit test:
- no
- Justification for study design:
- SPECIFICATION OF STUDY DESIGN FOR EXTENDED ONE-GENERATION REPRODUCTION TOXICITY STUDY WITH JUSTIFICATIONS [please address all points below]:
- Premating exposure duration for parental (P0) animals: 14 days
- Basis for dose level selection: The doses of 0, 100, 300 and 1000 mg/kg body weight for vehicle control/vehicle control recovery, low dose, mid dose and high dose/ high dose recovery groups respectively were selected in consultation with the sponsor based on the results of dose range finding study of test item Hostastat FE 20 LIQ when administered through oral gavage for a period of 14 consecutive days to Sprague Dawley Rats (Bioneeds Study No.: BIO-TX 1944).
These doses were selected as the test item Hostastat FE 20 LIQ when administered orally to Sprague Dawley rats once daily for 14 consecutive days did not reveal any treatment related effects at all the tested doses (100, 300 and 1000 mg/kg body weight).
- Route of administration: Oral - Specific details on test material used for the study:
- SOURCE OF TEST MATERIAL
- lot/batch No.of test material: ESD0021912
- Expiration date of the lot/batch: 17.03.2020
- Purity test date: 100 % [w/w]
STABILITY AND STORAGE CONDITIONS OF TEST MATERIAL
- Storage condition of test material: Ambient (21 to 29°C)
- Solubility and stability of the test substance in the vehicle: Vehicle used was corn oil and test item formulation was stable for 24 hours at room temperature
FORM AS APPLIED IN THE TEST: Liquid - Species:
- rat
- Strain:
- Sprague-Dawley
- Details on species / strain selection:
- Rat is one of the standard laboratory rodent species used for toxicity assessment and also recommended by various regulatory authorities.
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: In-house bred animals
- Females nulliparous and non-pregnant: yes
- Age at study initiation: 10 weeks
- Weight at study initiation: Male: 220 to 260 g
Female: 200 to 240 g
- Housing: standard polypropylene cage (size: L 430 x B 285 x H 150 mm)
- Diet (e.g. ad libitum): Teklad Certified (2014SC) Global 14 % Protein Rodent Maintenance Diet - Pellet (Manufactured by Envigo)
- Water (e.g. ad libitum): Deep bore-well water passed through activated charcoal filter and exposed to ultraviolet rays in Aquaguard water filter with purifier
- Acclimation period: 29 September 2016 to 17 October 2016
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 19.6 to 22.9oC
- Humidity (%): 48 to 69%
- Air changes (per hr): 12 to 15 air changes per hour
- Photoperiod (hrs dark / hrs light): 12 hours fluorescent light and 12 hours dark cycle
IN-LIFE DATES: From: 18 October 2016 To: 24 December 2016 - Route of administration:
- oral: gavage
- Vehicle:
- corn oil
- Details on exposure:
- Test item formulation was prepared daily before administration
- Details on mating procedure:
- - M/F ratio per cage: 1:1
- Length of cohabitation: 21 days
- Proof of pregnancy: sperm in vaginal smear referred to as day 0 of pregnancy
- After 14 days of unsuccessful pairing replacement of first male by another male with proven fertility.
- Further matings after two unsuccessful attempts: no
- After successful mating each pregnant female was caged (how): females were housed individually
- Any other deviations from standard protocol: No - Analytical verification of doses or concentrations:
- yes
- Remarks:
- during first week and week 5 of treatment
- Details on analytical verification of doses or concentrations:
- vehicle control/ vehicle control recovery: 0 mg/mL
Low dose: 10 mg/mL
Mid dose: 30 mg/mL
High dose/ high dose recovery: 100 mg/mL - Duration of treatment / exposure:
- Males: 37 days
Females: Approximately 70 days including premating, mating, gestation and lactation periods. - Frequency of treatment:
- Once daily
- Details on study schedule:
- - Age at mating of the mated animals in the study: 13 to 14 weeks
- Dose / conc.:
- 0 mg/kg bw/day (actual dose received)
- Remarks:
- vehicle control/vehicle control recovery
- Dose / conc.:
- 100 mg/kg bw/day (actual dose received)
- Remarks:
- Low dose
- Dose / conc.:
- 300 mg/kg bw/day (actual dose received)
- Remarks:
- Mid dose
- Dose / conc.:
- 1 000 mg/kg bw/day (actual dose received)
- Remarks:
- High dose/high dose recovery
- No. of animals per sex per dose:
- Main group: 12 male and 12 female per dose
Recovery group: 05 male and 05 female per dose - Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: The doses of 0, 100, 300 and 1000 mg/kg body weight for vehicle control/vehicle control recovery, low dose, mid dose and high dose/ high dose recovery groups respectively were selected in consultation with the sponsor based on the results of dose range finding study of test item Hostastat FE 20 LIQ when administered through oral gavage for a period of 14 consecutive days to Sprague Dawley Rats (Bioneeds Study No.: BIO-TX 1944).
These doses were selected as the test item Hostastat FE 20 LIQ when administered orally to Sprague Dawley rats once daily for 14 consecutive days did not reveal any treatment related effects at all the tested doses (100, 300 and 1000 mg/kg body weight)
- Rationale for animal assignment: The animals were weighed and arranged in ascending order of their body weights. These body weight stratified animals were distributed to all the groups using Microsoft Excel Spreadsheet, such that body weight variation of animals selected for the study did not exceed ± 20% - Positive control:
- Not applicable
- Parental animals: Observations and examinations:
- CAGE SIDE OBSERVATIONS: Yes
- Once daily throughout the experimental period.
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: weekly once
BODY WEIGHT: Yes
- Time schedule for examinations: The main group animals were weighed at receipt, on the first day of dosing, weekly thereafter and at termination. The females were weighed on gestation days 0, 7, 14 and 20 during pregnancy and on days 1, 4, 7 and 13 during lactation period. The recovery group animals were weighed at receipt, on the first day of dosing, weekly thereafter and at termination - Oestrous cyclicity (parental animals):
- Oestrus cycles were monitored during the acclimatization to evaluate its normal oestrus cyclicity (4 to 5 days). Only females with normal oestrus cyclicity were selected for the treatment. Vaginal smears were monitored daily from the beginning of the treatment period until evidence of mating. When obtaining vaginal/cervical cells, care was taken to avoid disturbance of mucosa, which may induce pseudopregnancy. Oestrus cyclicity was also monitored on the day of sacrifice for females. Recovery group females were not evaluated for oestrus cyclicity
- Sperm parameters (parental animals):
- Not applicable
- Litter observations:
- The day of littering was considered as lactation day 1. The number of pups born (dead and live) in a litter, sex and external observations were recorded at birth. Individual body weight of live pups on lactation day 1 (within 24 hours of parturition), 4, 7 and 13 was recorded. The anogenital distance of each pup was measured on postnatal day 4 (lactation day 4). The number of nipples/areolae in male pups were counted on postnatal day 13 (lactation day 13)
- Postmortem examinations (parental animals):
- SACRIFICE
- Male Animals: All Animals
- Female Animals: All animals were sacrificed on Lactation day 14.
GROSS NECROPSY
- Gross necropsy consisted of external and internal examinations including the cervical, thoracic, and abdominal viscera: Yes
HISTOPATHOLOGY / ORGAN WEIGHTS
Control and high dose groups examined, examination range at least according to guideline, with special emphasis on stages of spermatogenesis in the male gonads and histopathology of interstitial testicular cell structure - Postmortem examinations (offspring):
- The pups were sacrificed on lactation day 13 and the sacrificed pups and dead pups were examined for gross abnormalities and the findings were recorded.
- Statistics:
- (SPSS software version 22)
One-way ANOVA with Dunnett’s post test
Kruskal-Wallis followed by the Mann-Whitney test if differences were indicated
Chi-square test/ Fischer's Exact Test
The Parameters include Body weight , Change in body weight, Feed consumption, Copulatory interval, Gestation length, Hematology, Clinical chemistryAbsolute organ weights, Relative organ weights, FOB, Body temperature, Defecation, Urination, Rearing, Grip strength, Litter weights , Pup weight , Pre implantation loss, Pre natal loss
Post natal loss, Total No. of early/late resorptions/dam, Corpora lutea/dam, Implantations/dam, No. of pups/dam, Sex ratio, Mean litter size, Mean pup weight, Pregnancy rate, No. of dams with/without live pups, No. of dams with/without dead pups, No. of litters with/without resorptions. - Reproductive indices:
- Male Fertility Index (%) = Number of Males Impregnating Females
------------------------------------------------- x 100
Number of Males used for Mating
Female Fertility Index (%) = Number of Females confirmed with Pregnancy
--------------------------------------------------------- x 100
Number of Females used for Mating
Parturition (%) = Number Of Parturitions
------------------------------- x 100
Number Of Pregnancies
Copulatory Interval (Days) = Date of Initiation of Cohabitation - Date of Confirmation of Mating
Gestation Length (days) = Date of Delivery - Date of Confirmation of Mating - Offspring viability indices:
- Male/Female Sex Ratio = Number Male Pups Per Dam
-----------------------------------
Number Female Pups Per Dam
Live Birth Index (%) = Number Of Viable Pups Born
------------------------------------ x 100
Number Of Pups Born
Lactation Day 4
Pup Survival Index (%) = Number Of Viable Pups on Lactation Day 4
----------------------------------------------------- x 100
Number Of Pups Born
Lactation Day 7
Pup Survival Index (%) = Number Of Viable Pups on Lactation Day 7
------------------------------------------------------ x 100
Number Of Viable Pups on Lactation Day 4
Lactation Day 13 Pup Survival Index (%) = Number Of Viable Pups on Lactation Day 13
------------------------------------------------------- x 100
Number Of Viable Pups on Lactation Day 7 - Clinical signs:
- no effects observed
- Description (incidence and severity):
- There were no clinical signs of toxicity observed at any of the tested dose main groups of either sex during premating period and mating period, during post mating period in males, during gestation/l
actation period in females and throughout the experimental period in recovery group animals.
The detailed clinical examination of animals did not reveal any treatment related changes at any of the main and recovery group animals of either sex. - Dermal irritation (if dermal study):
- not specified
- Description (incidence and severity):
- Not applicable
- Mortality:
- no mortality observed
- Description (incidence):
- There were no mortality/morbidity observed at any of the tested dose main groups of either sex during premating period and mating period, during post mating period in males, during gestation/lactation
period in females and throughout the experimental period in recovery group animals. - Body weight and weight changes:
- no effects observed
- Description (incidence and severity):
- There were no treatment related changes in mean body weight and percent change in body weight with respect to day 1 at any of the main and recovery group animals of either sex
- Food consumption and compound intake (if feeding study):
- no effects observed
- Description (incidence and severity):
- There were no treatment related changes noted in feed consumption at any of the doses at any of the main and recovery group animals of either sex.
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- no effects observed
- Description (incidence and severity):
- There were no ocular changes observed in vehicle control and high dose group animals during the ophthalmological examination for males conducted at the end of the dosing period, for females during
the lactation period and for recovery group animals at the end of recovery period. - Haematological findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- There were no treatment related changes observed in haematology at any of the tested doses of either sex. However, statistically significant decrease in prothrombin time in low, mid and high dose group females and statistically significant increase in activated prothrombin time in the recovery group females when compared with vehicle control was noted. This change is considered as incidental and not treatment related, as the values are within historical control range and same changes not observed in males
- Clinical biochemistry findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- There were no treatment related changes observed in clinical chemistry at any of the doses tested in both sexes.
However, in main group males statistically significant decrease in alkaline phosphatase level at low dose and statistically significant increase in sodium level at mid and high dose noted when compared with vehicle control. In females, statistically significant increase in cholesterol at mid dose, statistically
significant increase in albumin at high dose and statistically significant increase in calcium at high dose were noted when compared with vehicle control.
In recovery males, statistically significant increase in creatinine, total protein, albumin, and chloride and statistically significant decrease in phosphorous at recovery when compared with vehicle control and in recovery females statistically significant increase in creatinine, cholesterol, albumin and sodium
and statistically significant decrease in phosphorous at recovery when compared with vehicle control was noted.
These changes are considered as an incidental and not treatment related, as the values are within historical control range and is due to biological variations.
Statistically significant decrease in T4 levels in high dose males when compared with vehicle control group were noted when compared with vehicle control group. The variation observed in the T4 levels could not be attributed as treatment related as there were no microscopic observations noted in thyroid gland and no effects were noted in thyroid weight at all the tested dose groups. This significant variation could be due to the increased T4 levels in vehicle control group males (Animal No. Rb8893: 99.593 ng/mL and Animal No. Rb8898: 99.416 ng/mL) and low dose group male (Animal No. Rb8905: 110.605 ng/mL). The T4 levels obtained across the groups are within historical control range. Hence, the variation observed in the T4 levels is considered to be incidental - Urinalysis findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- There were no treatment related changes observed at any of the dose tested. However, statistically significant decrease in urine volume at mid dose (males), significant decrease in urobilinogen in low, mid and high dose males and significant increase in pH at the end of recovery (females) was noted. This change is considered as an incidental and not treatment related, as the values are within historical control range.
- Behaviour (functional findings):
- no effects observed
- Description (incidence and severity):
- The detailed clinical examination of animals did not reveal any treatment related changes at any of the main and recovery group animals of either sex.
There were no changes observed in the neurological/functional examination conducted for main group males (prior to scheduled sacrifice), for main group females during the lactation period (prior to scheduled sacrifice) and for all recovery group animals at the end of recovery period. - Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, non-treatment-related
- Histopathological findings: non-neoplastic:
- effects observed, non-treatment-related
- Description (incidence and severity):
- There were no treatment related histopathological findings noticed in high dose group animals.
Testes, which were screened with special emphasis on stages of spermatogenesis and interstitial testicular cell structure, revealed normal progression of the spermatogenic cycle and presence of all expected associations.
All other observed histopathological lesions in high dose group animals, considered as spontaneous and incidental to Sprague Dawley rats of this particular age as they lack in consistency. - Histopathological findings: neoplastic:
- not examined
- Other effects:
- no effects observed
- Description (incidence and severity):
- There were no treatment related changes in gestation and lactation body weight, percent change in gestation and lactation body weights, feed consumption during gestation period and lactation period, uteri observations, litter and pup weights, anogenital distance of pups
- Reproductive function: oestrous cycle:
- no effects observed
- Description (incidence and severity):
- There were no changes observed in the oestrus cyclicity of females at any of the doses tested during pre-mating treatment, mating treatment and on lactation day 14.
- Reproductive function: sperm measures:
- not examined
- Reproductive performance:
- no effects observed
- Description (incidence and severity):
- There were no changes observed in number of corpora lutea, implantations, resorptions, pre-implantation loss and pre/post natal losses at any of the tested doses.
There were no treatment related changes in the gestation length,in the gestation length, litter delivered, number of pups delivered, sex ratio, live birth index and observation of litter on lactation day 1 to 13 at any of the tested doses. - Key result
- Dose descriptor:
- NOAEL
- Effect level:
- >= 1 000 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: absence of treatment-related adverse effects
- Key result
- Critical effects observed:
- no
- Clinical signs:
- no effects observed
- Dermal irritation (if dermal study):
- not specified
- Mortality / viability:
- no mortality observed
- Description (incidence and severity):
- There were no changes observed in implantations, resorptions, pre-implantation loss and pre/post natal losses at any of the tested doses.
There were no treatment related changes in number of pups delivered and live birth index and observation of litter on lactation day 1 to 13 at any of the tested doses. - Body weight and weight changes:
- effects observed, non-treatment-related
- Description (incidence and severity):
- There were changes observed in mean pup weight during lactation day 1 to 13 at any of the doses tested. However, statistically significant increase in mean male pup weight on lactation day 7 in the mid dose group and mean female pup weight on lactation day 7 in low and mid dose groups was noted when compared with vehicle control. This can be considered as incidental and not to be treatment related as there were no external observations noted in these pups.
- Food consumption and compound intake (if feeding study):
- not examined
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Statistically significant decrease in T4 levels of pups on lactation day 13 at G2, G3 and G4 groups were noted when compared with vehicle control group.
The variation observed in the T4 levels could not be attributed as treatment related as there were no microscopic observations noted in thyroid gland and no effects were noted in thyroid weight at all the tested dose groups. This significant variation could be due to the increased T4 levels in vehicle control group pups (Animal No. Rb8945/Pup No. 2 & 3: 98.703 ng/mL, Rb8948/Pup No. 2 & 3: 91.128 ng/mL), low dose group pups (Animal No. Rb8957/Pup No. 2 & 3: 90.457 ng/mL). The T4 levels obtained in pups across the groups are within historical control range. Hence, the variation observed in the T4 levels is considered to be incidental. - Urinalysis findings:
- not examined
- Sexual maturation:
- not examined
- Organ weight findings including organ / body weight ratios:
- not examined
- Gross pathological findings:
- no effects observed
- Description (incidence and severity):
- There were no gross pathological changes (both external and internal) observed at any of the doses tested in pups of both sexes
- Histopathological findings:
- not examined
- Other effects:
- no effects observed
- Description (incidence and severity):
- There were no changes observed in anogenital distance of both male and female pups at any of the tested doses.
There were no occurrences of nipples in male pups at any of the tested doses on lactation day 13. - Behaviour (functional findings):
- not examined
- Developmental immunotoxicity:
- not examined
- Key result
- Dose descriptor:
- NOAEL
- Generation:
- F1
- Effect level:
- 1 000 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: absence of treatment-related adverse effects
- Key result
- Critical effects observed:
- no
- Key result
- Reproductive effects observed:
- no
- Conclusions:
- Based on the results discussed, the No Observed Adverse Effect Level (NOAEL) of the test item was found to be 1000 mg/kg body weight when administered to the males for two weeks pre-mating, during mating and up to the day before sacrifice during post-mating period (total of 37 days), and to the females for two weeks pre-mating, during mating, pregnancy (gestation) and up to lactation day 13 under the experimental conditions employed in this study.
- Executive summary:
The test item, was evaluated for possible adverse effects following repeated oral dosing to males for 37 days and to females, two weeks pre-mating period, during mating, pregnancy (gestation) and up to lactation day 13 to evaluate effects of test item on male and female reproductive performance such as gonadal function, mating behavior, conception, development of the conceptus,
parturition, and early neonatal development. A total of 116 (58 males + 58 females) Sprague Dawley rats were distributed to four main groups and two recovery groups. G1 (control), G2 (low dose), G3 (mid dose) and G4 (high dose) groups consisted of 12 males and 12 females and each recovery group (G1R and G4R) consisted of 5 males and 5 females. The animals in G1/G1R group were administered with vehicle[Corn oil], the animals in G2, G3 and G4/ G4R groups were administered with test item at the dose levels of 100, 300 and 1000 mg/kg body weight for low dose, mid dose and high dose/high dose recovery groups respectively. The vehicle and test item formulations were administered orally by gavage at the dose volume of 10 mL/kg body weight. The main group males were treated for two weeks pre-mating, during mating and up to the day before sacrifice during post-mating period (total of 37 days of treatment). The main group females were treated for two weeks pre-mating period, during mating, pregnancy (gestation) and up to lactation day 13 after which the pups were sacrificed on lactation Day 13 and females (dams) were sacrificed on lactation day 14 after overnight fasting (water allowed). The recovery group males and females were treated until the first scheduled sacrifice of dams and kept without treatment for a further 16 days observation. The dose formulation analysis for homogeneity and concentration verification was performed during weeks 1 and 5 of the treatment period and the results were within acceptable limits.
All animals were observed for clinical signs, mortality and morbidity, detailed clinical examination, body weight and feed consumption. Ophthalmological examination was carried out once before treatment for all animals, duringend of the dosing period for males (shortly prior to scheduled sacrifice) and during lactation period for females (shortly prior to scheduled sacrifice) for vehicle control and high dose group animals andduring last weekfor recovery group animals.Neurological/Functional examination was performed for five males and five females, randomly selected from each group towards the end of the dosing period for males (shortly prior to scheduled sacrifice), during lactation period for females (shortly prior to scheduled sacrifice) and from both the recovery group animals towards the end of the recovery period (shortly prior to scheduled sacrifice.
The clinical pathology (haematological and clinical chemistry) examinations were conducted in five males and five females from each main group (randomly selected) andfor all recovery group animals. Urinalysis was performed from the five randomly selected males of each main group during the last week of the treatment period and for all recovery animals at termination.
Each litter was examined after delivery (lactation day 1) and the number and sex of pups (litter size), stillbirths (dead pups born on day 1) and live births were recorded.
Body weights of male and female pups were recorded separately on lactation days 1, 4, 7 and 13.The anogenital distance of each pup was measured on lactation day 4. The number of nipples/areolae in male pups were counted on lactation day 13.
Gross pathology and organ weighing were performed on day 38 for males, on lactation day 13 for pups, lactation day 14 for dams and on day 68 for recovery group animals. The number of corpora lutea, implantation sites and resorptions for dams were recorded.
The animals did not reveal any clinical signs of toxicity. No mortality or morbidity was observed throughout the experimental period. No treatment related changes in body weight, percent change in body weight, feed consumption, ophthalmoscopic examination, neurological/functional examination, haematology, clinical chemistry, urine analysis nor in organ weights (both absolute and relative) were observed in both the sex of main and recovery group animals.
The dams did not reveal any treatment related changes in gestation and lactation body weight, percent change in gestation and lactation body weights, feed consumption during gestation period and lactation period, uteri observations, litter and pup weights, anogenital distance of pups.
There were no treatment related changes observed in mean pup weight during lactation day 1 to 13 at any of the doses tested.
There were no changes observed in anogenital distance of both male and female pups at any of the tested doses.
There were no occurrences of nipples in male pups at any of the tested doses on lactation day 13.
Statistically significant decrease in T4 levels of pups on lactation day 13 at G2, G3 and G4 groups were noted, but considered to be incidental.
The animals did not reveal any treatment related gross pathological and histopathological findings
Reference
The dose formulation analysis for concentration verification was performed during week 1 and 5 of treatment period and the results were within acceptable limits.
Effect on fertility: via oral route
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 1 000 mg/kg bw/day
- Study duration:
- subacute
- Species:
- rat
- Quality of whole database:
- Reliable study, GLP-compliant and according to OECD guideline 422
Effect on fertility: via inhalation route
- Endpoint conclusion:
- no study available
Effect on fertility: via dermal route
- Endpoint conclusion:
- no study available
Additional information
In this GLP-compliant study according to OECD guideline 422 the test item was administered daily (gavage) to male and female Sprague-Dawley rats at dose levels of 100, 300 and 1000 mg/kg bw/day. No effects were observed with respect to parental toxicity, effects on reproduction and development of pups.
Effects on developmental toxicity
Description of key information
Developmental effects were examined in the OECD 422 study (see above) and no effects were observed.
Effect on developmental toxicity: via oral route
- Endpoint conclusion:
- no study available
- Quality of whole database:
- Developmental effects were examined in the OECD 422 study (see above) and no effects were observed
Effect on developmental toxicity: via inhalation route
- Endpoint conclusion:
- no study available
Effect on developmental toxicity: via dermal route
- Endpoint conclusion:
- no study available
Additional information
In this GLP-compliant study according to OECD guideline 422 the test item was administered daily (gavage) to male and female Sprague-Dawley rats at dose levels of 100, 300 and 1000 mg/kg bw/day. No effects were observed with respect to parental toxicity, effects on reproduction and development of pups.
Toxicity to reproduction: other studies
Additional information
In this GLP-compliant study according to OECD guideline 422 the test item was administered daily (gavage) to male and female Sprague-Dawley rats at dose levels of 100, 300 and 1000 mg/kg bw/day. No effects were observed with respect to parental toxicity, effects on reproduction and development of pups.
Mode of Action Analysis / Human Relevance Framework
In the absence of any evidence for species specific effects or modes of action possibly observed effects would be regarded as relevant for humans.
Justification for classification or non-classification
As no reproductive or developmental effects were oberved up to the highest dose (1000 mg/kg bw/day), no classification is required according to Regulation (EC) No. 1272/2008 (CLP).
Additional information
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.